Zobrazeno 1 - 10
of 76
pro vyhledávání: '"Kousuke Watanabe"'
Autor:
Kousuke Watanabe, Shinji Kohsaka, Kenji Tatsuno, Aya Shinozaki-Ushiku, Hideaki Isago, Hidenori Kage, Tetsuo Ushiku, Hiroyuki Aburatani, Hiroyuki Mano, Katsutoshi Oda
Publikováno v:
Practical Laboratory Medicine, Vol 39, Iss , Pp e00368- (2024)
Background: The nucleic acid quality from formalin-fixed paraffin-embedded (FFPE) tumor vary among samples, resulting in substantial variability in the quality of comprehensive cancer genomic profiling tests. The objective of the study is to investig
Externí odkaz:
https://doaj.org/article/62e1e12604dc4f56af60b6158cae988d
Autor:
Katsunori Manaka, Junichiro Sato, Maki Takeuchi, Kousuke Watanabe, Hidenori Kage, Taketo Kawai, Yusuke Sato, Takuya Miyagawa, Daisuke Yamada, Haruki Kume, Shinichi Sato, Takahide Nagase, Taroh Iiri, Masaomi Nangaku, Noriko Makita
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-10 (2021)
Abstract Immune checkpoint inhibitors (ICIs) are potent therapeutic options for many types of advanced cancer. The expansion of ICIs use however has led to an increase in immune-related adverse events (irAEs). Secondary adrenal insufficiency (AI) can
Externí odkaz:
https://doaj.org/article/17fdf79d6b164cec9a920dc3a38ae5d0
Autor:
Kazuhiro Yoshiuchi, Gary Rodin, Yutaka Matsuyama, KEN SHIMIZU, Seraki Miyamoto, Tadahiro Yamazaki, Toshio Matsubara, Hidenori Kage, Kousuke Watanabe, Hiroshi Kobo
Publikováno v:
BMJ Open, Vol 12, Iss 3 (2022)
Introduction Managing Cancer and Living Meaningfully (CALM) is a novel, brief and manualised psychotherapeutic intervention intended to treat and prevent depression and end-of-life distress in patients with advanced cancer. This phase 2 trial aims to
Externí odkaz:
https://doaj.org/article/94a13b5352ad4d8d962d51f2412ec8c8
Autor:
Masanobu Abe, Kousuke Watanabe, Aya Shinozaki-Ushiku, Tetsuo Ushiku, Takahiro Abe, Yuko Fujihara, Yosuke Amano, Liang Zong, Cheng-Ping Wang, Emi Kubo, Ryoko Inaki, Naoya Kinoshita, Satoshi Yamashita, Daiya Takai, Toshikazu Ushijima, Takahide Nagase, Kazuto Hoshi
Publikováno v:
BMC Cancer, Vol 19, Iss 1, Pp 1-7 (2019)
Abstract Background Cancers of unknown primary origin (CUPs) are reported to be the 3-4th most common causes of cancer death. Recent years have seen advances in mutational analysis and genomics profiling. These advances could improve accuracy of diag
Externí odkaz:
https://doaj.org/article/38df80730bb3400da14ad1b00032922d
Autor:
Kousuke Watanabe, Hidenori Kage, Saki Nagoshi, Kazuhiro Toyama, Yoshiyuki Ohno, Aya Shinozaki-Ushiku, Kumi Nakazaki, Hiroshi Suzuki, Mineo Kurokawa, Takahide Nagase
Publikováno v:
Case Reports in Oncological Medicine, Vol 2020 (2020)
Tyrosine kinase inhibitor (TKI) combination is expected to increase in the era of precision medicine. TKI combination may be required to treat double primary cancers, each having a targetable gene, or to treat a single malignancy with multiple target
Externí odkaz:
https://doaj.org/article/8fcdd5764b2e4f14b6e73c84355893f0
Autor:
Kousuke Watanabe, Atsushi Yasumoto, Yosuke Amano, Hidenori Kage, Yasushi Goto, Yutaka Yatomi, Daiya Takai, Takahide Nagase
Publikováno v:
PLoS ONE, Vol 13, Iss 9, p e0203625 (2018)
BACKGROUND:A growing body of evidence supports the role of platelets in cancer metastasis, escape from immune surveillance, and angiogenesis. Mean platelet volume (MPV), which reflects platelet turnover, is reported routinely as part of automated com
Externí odkaz:
https://doaj.org/article/5de5ab2d2eab47efbe5888fe14f1c1d7
Autor:
Hidenori Kage, Aya Shinozaki‐Ushiku, Kazunaga Ishigaki, Yusuke Sato, Masahiko Tanabe, Shota Tanaka, Michihiro Tanikawa, Kousuke Watanabe, Shingo Kato, Kiwamu Akagi, Keita Uchino, Kinuko Mitani, Shunji Takahashi, Yuji Miura, Sadakatsu Ikeda, Yasushi Kojima, Kiyotaka Watanabe, Hitoshi Mochizuki, Hironori Yamaguchi, Yoshimasa Kawazoe, Kosuke Kashiwabara, Shinji Kohsaka, Kenji Tatsuno, Tetsuo Ushiku, Kazuhiko Ohe, Yutaka Yatomi, Yasuyuki Seto, Hiroyuki Aburatani, Hiroyuki Mano, Kiyoshi Miyagawa, Katsutoshi Oda
Publikováno v:
Cancer science.
Comprehensive cancer genome profiling (CGP) has been nationally reimbursed in Japan since June 2019. Less than 10% of the patients have been reported to undergo recommended treatment. Todai OncoPanel (TOP) is a dual DNA-RNA panel as well as a paired
Autor:
Haruki Kume, Taketo Kawai, Maki Takeuchi, Masaomi Nangaku, Hidenori Kage, Kousuke Watanabe, Yusuke Sato, Katsunori Manaka, Noriko Makita, Daisuke Yamada, Takahide Nagase, Shinichi Sato, Taroh Iiri, Takuya Miyagawa, Junichiro Sato
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-10 (2021)
Scientific Reports
Scientific Reports
Immune checkpoint inhibitors (ICIs) are potent therapeutic options for many types of advanced cancer. The expansion of ICIs use however has led to an increase in immune-related adverse events (irAEs). Secondary adrenal insufficiency (AI) can be life-
Autor:
Hidenori Kage, Shinji Kohsaka, Kenji Tatsuno, Aya Shinozaki-Ushiku, Hideaki Isago, Kousuke Watanabe, Motohiro Kato, Tetsuo Ushiku, Kiyoshi Miyagawa, Takahide Nagase, Jun Nakajima, Hiroyuki Aburatani, Hiroyuki Mano, Katsutoshi Oda
Publikováno v:
Cancer Research. 83:256-256
Introduction: Comprehensive cancer genomic profiling tests have been implemented in the clinic to guide patients and physicians to decide optimal treatments. Most tests analyze genomic DNA to detect genomic alterations in a few hundred genes. RNA pan
Autor:
Seraki Miyamoto, Tadahiro Yamazaki, Ken Shimizu, Toshio Matsubara, Hidenori Kage, Kousuke Watanabe, Hiroshi Kobo, Yutaka Matsuyama, Gary Rodin, Kazuhiro Yoshiuchi
Publikováno v:
BMJ open. 12(3)
IntroductionManaging Cancer and Living Meaningfully (CALM) is a novel, brief and manualised psychotherapeutic intervention intended to treat and prevent depression and end-of-life distress in patients with advanced cancer. This phase 2 trial aims to